Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recoflavone - Dong-A ST

Drug Profile

Recoflavone - Dong-A ST

Alternative Names: DA-6034; GLH8NDE

Latest Information Update: 04 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer Dong-A Pharmaceutical; Dong-A ST
  • Class Anti-inflammatories; Antiallergics; Benzopyrans; Eye disorder therapies; Flavonoids; Small molecules
  • Mechanism of Action Antioxidants; Calcium channel agonists; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Dry eyes; Gastritis

Highest Development Phases

  • Phase III Gastritis
  • Discontinued Crohn's disease; Dry eyes; Ulcerative colitis

Most Recent Events

  • 26 Sep 2019 GL Pharm Tech Corporation plans a phase I trial (In volunteers) for Dry eyes in South Korea (Ophthalmic,Drops) (NCT04104997)
  • 11 Jul 2019 Discontinued - Phase-II for Dry eyes in South Korea (Ophthalmic) (NDR batch #16)
  • 03 Sep 2015 Phase-II development is ongoing for Dry eyes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top